At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SRRA Sierra Oncology Inc
Halted 06-30 16:00:00 EDT
54.99
+0.00
0.00%
High54.99
Low54.99
Vol0.00
Open54.99
D1 Closing54.99
Amplitude0.00%
Mkt Cap1.34B
Tradable Cap737.99M
Total Shares24.42M
T/O47.45M
T/O Rate0.00%
Tradable Shares13.42M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Introduction
Company Name.
Sierra Oncology Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.